Berberine Prevent Contrast-induced Nephropathy in Patients With Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 800 participants.

Also called NCT02808351

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 800 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02808351
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02808351. Randomized; single masking; primary purpose treatment. Start 2016-07 (actual); primary completion 2021-12 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Berberine Prevent Contrast-induced Nephropathy in Patients With Diabetes
Condition
Diabetes Mellitus
Intervention (Drug)
Berberine
Lead sponsor
Nanjing First Hospital, Nanjing Medical University (class: other)

Record details

Record id
cardio:ct-nct02808351
Content hash
9f33b5303fd73082e98fda67da003d38092a23c6103f8c7b9a82dc507fe59b16